- Source type
- Article
- Access type
- Publisher
- Publisher
- The Guardian
- Date
- 2025-10-20
- Added
- 2026-07-09
Trust profile
VV Source Trust Matrix v1.0
VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.
60
General published source
- Publisher type
- General media
- Bias profile
- Elevated
This source is strongest for consumer context and regulatory status and weaker for safety and trial discovery.
VV Source Fit Score 1.0
Fit by use case
Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.
- Regulatory status
- 54/100
- Weak Support
- Clinical outcomes
- 54/100
- Weak Support
- Mechanism
- 54/100
- Weak Support
- Safety
- 54/100
- Weak Support
- Consumer context
- 67/100
- Context Source
- Trial discovery
- 54/100
- Weak Support
Best used for
- Context
- Public narrative
Weak for
- Clinical claims
- Safety conclusions
- Regulatory status
Used in Viral Vitalism
Tiny Retinal Implant Helped Some Blind Patients Read Again
Roles: Background
Show section-level references
- The PRIMA retinal implant, paired with camera-equipped glasses and training, helped many participants with severe age-related macular degeneration regain limited central visual function, including reading ability. This is partial prosthetic vision restoration, not normal vision, not a cure for blindness, and not yet broadly approved in the U.S.Older corroborating report; useful for context but not a fresh July 2026 trigger by itself.
Related studies
No structured study record is currently attached to this source.
Related sources
ClinicalTrials.gov: KIO-301 ABACUS-1 trial
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 0 connections
Reuters Health Rounds: PRIMA retinal implant context
Older independent context; should not be treated as a new July 2026 news peg.
- Trust score
- 60
- Publisher
- Reuters
- Access
- Publisher
- Usage
- 1 connection
San Francisco Chronicle: PRIMA retinal implant reporting
Patient-facing reporting; add primary device/trial source before publishing as a rapid brief.
- Trust score
- 60
- Publisher
- San Francisco Chronicle
- Access
- Publisher
- Usage
- 1 connection
Medical Xpress / University of Adelaide: photoswitch drug first human trial
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 60
- Publisher
- Medical Xpress / University of Adelaide
- Access
- Publisher
- Usage
- 0 connections
REGENXBIO: first patient dosed in Phase IIb/III NAAVIGATE trial
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 60
- Publisher
- REGENXBIO
- Access
- Publisher
- Usage
- 0 connections
REGENXBIO: pivotal program background for sura-vec in diabetic retinopathy
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 60
- Publisher
- REGENXBIO
- Access
- Publisher
- Usage
- 0 connections